Votrient: The dissolution is out of specification in the affected lot
Last updated
Summary
Product
Votrient
Issue
Health products - Product quality
What to do
Consult your health care professional if you have any health concerns.
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot |
|---|---|---|---|---|---|
Votrient |
Votrient |
DIN 02352303 |
Tablet |
PAZOPANIB (PAZOPANIB HYDROCHLORIDE) 200 MG |
MJ5389 |
Issue
The dissolution is out of specification in the affected lot.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
Novartis Pharmaceuticals Canada Inc.
100 700 rue St-Hubert, Montréal
Québec H2Y 0C1
Published by
Health Canada
Audience
General public
Healthcare
Industry
Recall class
Type II
Identification number
RA-74593
Get notified
Receive notifications for new and updated recalls and alerts by category.